Page last updated: 2024-11-02

pirenzepine and Myopia, Pathological

pirenzepine has been researched along with Myopia, Pathological in 1 studies

Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Walline, JJ1
Lindsley, KB1
Vedula, SS1
Cotter, SA1
Mutti, DO1
Ng, SM1
Twelker, JD1

Reviews

1 review available for pirenzepine and Myopia, Pathological

ArticleYear
Interventions to slow progression of myopia in children.
    The Cochrane database of systematic reviews, 2020, 01-13, Volume: 1

    Topics: Atropine; Child; Contact Lenses; Cyclopentolate; Humans; Muscarinic Antagonists; Myopia, Degenerativ

2020